Articles

HUB programs ensure that cancer care is delivered efficiently. However, many patients and healthcare providers need more education on the services offered for these programs to be effective. In this session, experts discuss common challenges of HUB programs and the future of these support services.

The COVID-19 pandemic exposed many cracks in today’s healthcare system, including underrepresentation of minorities in clinical trials. In this session, experts discuss this important issue, as well as strategies for effectively breaking down current health equity barriers.

After Medicare, employers are the largest purchasing group in cancer care. In this session, experts offer employers’ perspectives on health benefit plans, as well as issues that frequently arise when designing plans, managing costs, and defining value.

The COVID-19 pandemic has significantly affected all areas of the healthcare system. In this session, experts offer pharmaceutical perspectives on the innovations that may result from the current public health crisis and the future of cancer care.

Cancer Centers of Excellence play an important role in the delivery of cancer care. Future expansion into the communities and remotely will benefit patients, employers, and payers, and may help to close health disparity gaps.

Greg Simon, who led the Cancer Moonshot program under the Obama-Biden administration, asserts that the COVID-19 pandemic has exposed vast chasms of inequity in cancer care, and challenges listeners to think in new ways about how we deliver and pay for care.

From new approaches for sequencing therapy to preparing for an incoming tsunami of delayed diagnoses after months of missed cancer screenings, community cancer providers have a lot to manage in the era of COVID-19.

From the CMS’s Oncology Care Model to future prospects for Oncology Care First and other value-based and alternative payment models, payers share their insights on what is most likely to succeed to improve care and manage costs in oncology.

From quality-adjusted life-years to social determinants of health to the international pricing index, top experts in cancer care economics discussed strategies for achieving the Holy Grail of true value-based pricing for pharmaceuticals.

At the July 2020 AACR virtual meeting on COVID-19 and cancer, Solange Peters, MD, PhD, European Society for Medical Oncology President, and Head, Medical Oncology Department, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, delivered the keynote address, providing an update on the COVID-19 and Cancer Consortium cohort study.